Skip to main content
Clinical Trials/NCT06236958
NCT06236958
Recruiting
Not Applicable

Clinical Study on the Effect of Early Enteral Nutrition Implemented by Placing Nasojejunal Tube During Ovarian Cancer Surgery on Patients' Postoperative Recovery and Prognosis

Luo Chengyan1 site in 1 country200 target enrollmentDecember 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Advanced Epithelial Ovarian Cancer
Sponsor
Luo Chengyan
Enrollment
200
Locations
1
Primary Endpoint
Quality of life scores
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

This is a single-center, unblinded, prospective observational study, and the objective is to compare the effects of enteral nutrition via nasojejunal tube and parenteral nutrition via vein on patients' early recovery and prognosis who undergo tumor cytoreduction for ovarian cancer.

Detailed Description

Ovarian cancer is the most lethal disease among gynecological malignancies, and its treatment is a comprehensive one mainly based on surgery. The perioperative nutritional status of patients affects their postoperative recovery, subsequent adjuvant therapy, and their prognosis. Hence, nutritional support therapy should be initiated for such patients in the early postoperative period to prevent further malnutrition. Conventional postoperative nutritional support therapy is performed through parenteral nutrition via vein, while the application of enteral nutrition via the nasojejunal tube in the postoperative period of ovarian cancer has not been reported in the literature. Therefore, in this study, the investigators took advantage of the characteristics of long surgical incisions and the wide surgical scope of ovarian cancer to investigate the effects of placing a nasojejunal tube during the operation and early enteral nutrition on postoperative recovery and prognosis in patients with advanced ovarian cancer, with the aim of accelerating the postoperative recovery of the patients, decreasing the incidence of postoperative complications, supplementing adjuvant chemotherapy in time, improving the survival outcome of the patients with advanced ovarian cancer, and providing gynecologists with a basis for enteral nutritional support therapy via nasojejunal tube after ovarian cancer surgery. In this study, the patients placed with a nasojejunal tube during the operation and enteral nutrition after the operation were included in the observation group, and the patients without a nasojejunal tube and parenteral nutrition after the operation were included in the control group. And the two groups were compared in terms of the indicators of postoperative recovery, the incidence of complications within the 30 days after operation, the cost of hospitalization, hospital stay, the interval between the operation and the first chemotherapy, the survival outcome, etc. The data involved in the study came from patient files, hospital databases, and long-term follow-up results.

Registry
clinicaltrials.gov
Start Date
December 1, 2023
End Date
December 1, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Luo Chengyan
Responsible Party
Sponsor Investigator
Principal Investigator

Luo Chengyan

chief physician

The First Affiliated Hospital with Nanjing Medical University

Eligibility Criteria

Inclusion Criteria

  • (1) The age is more than 18 years old and not more than 75 years old; (2) Ovarian cancer patients who are clearly diagnosed as epithelial ovarian cancer by pathological examination, whose tumors involve organs other than the pelvis as determined by preoperative imaging and intraoperative visual judgment, and who are at FIGO stage III or IV, and who undergo tumor cytoreductive surgery; (3) Patients without contraindication to nasoenteric tube placement and enteral nutrition; (4) Patients and their families were informed of the significance of the early use of enteral nutrition, precautions, adverse reactions, etc., before the operation, and they gave informed consent to this study and signed the informed consent; (5) Patients who received treatment in our hospital with complete clinical data.

Exclusion Criteria

  • (1) Patients with intestinal obstruction, severe intestinal infection, severe diarrhea, and acute abdomen right before surgery; (2) Patients with esophagogastric fundal varices and active gastrointestinal bleeding right before surgery; (3) Patients who undergo surgery to simultaneously resect the intestinal canal in the area more than 15cm distal to the ligament of Traitz; (4) Patients with severe cardiac, hepatic, and renal failure; (5) Patients with severe rhinitis, nasal mucous membrane damage, bleeding; (6) Patients with other malignant tumors combined within 3 months before surgery; (7) Metastatic ovarian cancer; (8) Those with missing clinical information; (9) Those with known hypersensitivity to enteral nutrition preparations.

Outcomes

Primary Outcomes

Quality of life scores

Time Frame: postoperative days 3

To assess patients' quality of life scores on postoperative day 3 according to functional assessment of cancer therapy-ovary cancer (FACT-O) vision 4.0, with a minimum value of 0 and a maximum value of 156. The higher scores are, the better quality of postoperative survival is.

Serum sodium and potassium

Time Frame: postoperative days 7, and 14

To record the patient's serum sodium and potassium on postoperative days 7 and 14 according to biochemical results.

Abnormal liver function

Time Frame: postoperative days 7, and 14

To record the number of patients with abnormal liver function within 30 days postoperatively according to biochemical results. Abnormal liver function was defined as serum alanine aminotransferase and/or aspartate aminotransferase higher than 2.5 times the upper limit of normal values.

Serum albumin

Time Frame: postoperative days 7, and 14

To record the patient's serum albumin on postoperative days 7 and 14 according to biochemical results.

Intervals from surgery to the initiation of postoperative exhaustion and defecation

Time Frame: one month after surgery

To record intervals from surgery to the initiation of postoperative exhaustion and defecation according to the medical record

The hospital stay after surgery and intervals from surgery to initiation of postoperative chemotherapy

Time Frame: one month after surgery

To record the hospital stay after surgery and intervals from surgery to initiation of postoperative chemotherapy according to the medical record

Incidence of complications postoperative complications

Time Frame: one month after surgery

To record the incidence of complications patient's postoperative complications for 30 days according to medical records, including: fever, intestinal obstruction, intestinal fistula, thrombosis, pulmonary embolism, poor incision healing, etc.

Hemoglobin

Time Frame: postoperative days 7, and 14

To record the patient's hemoglobin on postoperative days 7 and 14 according to routine blood results

The cost of hospitalization of peri operation

Time Frame: one month after surgery

To record the cost of a patient's hospitalization of peri operation according to the medical record

Abnormal renal function

Time Frame: postoperative days 7, and 14

To record the number of patients with abnormal renal function within 30 days postoperatively according to biochemical results. Abnormal renal function was defined as serum creatinine and/or urea higher than 2.5 times the upper limit of normal values.

Secondary Outcomes

  • Incidence of complications related to nasojejunal tubes(one month after surgery)
  • Survival outcomes(three years after surgery)

Study Sites (1)

Loading locations...

Similar Trials